Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

To the Editor: This post hoc analysis evaluated tildrakizumab efficacy, durability of response, and safety in patients with moderate to severe chronic psoriasis with vs without metabolic syndrome (MetS) using pooled data from 2 phase 3, double-blind, randomized, placebo-controlled studies, reSURFACE 1 (A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis [MK-3222-010]; NCT01722331) and reSURFACE 2 (A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab [SCH 900222/MK-3222] in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study [MK-3222-011]; NCT01729754).